<b>Gapping up <br/>In reaction to strong earnings/guidance</b>: TNXP +17.6%, AEO +15.5%, PERY +9.4%, ROX +8.4%, WMT +8%, URBN +7.8%, ZIOP +6.4%, CRM +6.1%, CSCO +4.8%, SQM +2.3%, SQM +2.3%, DKS +2.1%, HQCL +2%, FTI +1.4%, EXP +0.5%<br/><br/><b>M&A news</b>: CHD +8.8% (report that Reckitt (RBGLY) might bid for CHD), MON +7.6% (confirms receipt of non-binding proposal from Bayer (BAYRY)), FTI +1.2% (FMC Tech and Technip (TKPPY) to merge in all-stock transaction; combined company would have an equity value of $13 bln)<br/><br/><b>Select EU financial related names showing strength: </b>RBS +2.9%, CS +2.3%, HSBC +2%<br/><br/><br/><b>Other news:</b> RPRX +23.3% (reports 'positive' clinical data for Oral Proellex ), BIND +15.7% (reaches agreement in relation to its recent Chapter 11 filing for the use of cash collateral through July 8), GEVO +15% (enters into an agreement with Clariant), TNXP +14.5% (announces topline results of the Phase 2 dose-finding clinical study of TNX-102 SL in military-related PTSD), CPXX +10.7% (granted breakthrough therapy designation to Vyxeos), ZIOP +6.4% (to present interim results from its ongoing Phase 1, multi-center dose-escalation study of the gene therapy candidate Ad-RTS-hIL-12 + orally-administered veledimex in patients with recurrent or progressive glioblastoma at ASCO), ARRY +5.4% (to present present additional data on its late-stage candidates binimetinib and encorafenib in NRAS-mutant melanoma and BRAF-mutant colorectal cancer at ASCO), GALE +3.4% (to present primary analysis from the Company's GALE-301 Phase 1/2a clinical trial at ASCO), ARIA +2.7% (to present clinical data on brigatinib at ASCO), DB +1.9% (rovides 2020 financial objectives; Fitschen will step down as Co-Chairman of the Management Board of Deutsche Bank), POT +1.8% (in symp with MON), COST +1.1% (in sympathy with WMT)<br/><br/><b>Analyst comments:</b> N/A<br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance: </b>DRWI -21.6%, SSI -18.4%, CMCM -11.2%, AAP -10.5%, MNRO -6.3%, FLO -6.1%, LB -5.3%, OXLC -5.2%, TK -4.8%, TNK -3.3%, TTWO -2.6%, MBT -1.3%, NGG -1%<br/><br/><b>Select metals/mining stocks trading lower:</b> IAG -3.9%, HMY -2.4%, GG -2.3%, SLV -2.2%, KGC -2.2%, NEM -2.1%, VALE -1.9%, AU -1.9%, GDX -1.8%, FCX -1.7%, BBL -1.6%, BHP -1.4%, RIO -1.3%, AA -0.9%<br/><br/><b>Select oil/gas related names showing early weakness:</b> SDRL -4.3%, STO -2%, MRO -1.8%, RDS.A -1.7%, TOT -1.7%, WTI -1.4%<br/><br/><b>Other news: </b>HK -71.5% ( reaches agreement to restructure balance sheet with select note holders for the potential elimination of ~$1.8 bln of debt & ~$222 mln of preferred equity while reducing interest burden by more than $200 mln), GBSN -7.7% (holders of its senior secured convertible notes voluntarily removed restrictions on the Company's use of an aggregate of $1 mln previously funded to the Company and authorized the release of those funds from the restricted accounts of the Company), RGEN -7.3% ( files for mixed securities shelf offering; commences underwritten public offering of $100 mln aggregate principal amount of Convertible Senior Notes due 2021), HLT -4.6% (travel stocks under pressure after reports of missing Egypt plane), BLDR -4.4% (prices 13.26 mln share secondary public offering of common stock by selling shareholder), GLPI -3.4% (prices ~10.5 mln common stock offering by selling shareholders), IHG -2% (travel stocks under pressure after reports of missing Egypt plane), PFGC -1.2% (prices offering by selling shareholders of 12 mln shares of common stock at $24.25 per share)<br/><br/><b>Analyst comments: </b>BKU -0.9% (downgraded to Sell from Buy at Goldman)<br/><br/>Briefing.com